MAGE3 and Survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer

Li,Dong; He,Song

doi:10.3892/ol.2018.8362

MAGE3 and Survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer

Authors:
- Dong Li
- Song He
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Central Hospital of Zibo, Zibo, Shandong 250012, P.R. China, Maanshan Center for Clinical Laboratory, Maanshan, Anhui 243000, P.R. China
Published online on: March 28, 2018 https://doi.org/10.3892/ol.2018.8362
Pages: 8777-8783

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dendritic cell (DC) immunotherapy is an optimal cancer treatment, resulting in its emergence as a therapeutic choice; however, there are limited studies investigating dual antigen‑pulsed DC immunotherapy in non‑small cell lung cancer (NSCLC). In order to determine the effect of a recombinant melanoma‑associated antigen (rMAGE‑3) and recombinant Survivin (rSurvivin) peptide‑pulsed DC immunotherapy in patients with NSCLC, the present clinical study was performed. DC immunotherapy was generated from the monocytes of patients with NSCLC and primed with rMAGE‑3 and rSurvivin peptides. The present open‑label, non‑randomised study enrolled 16 patients with histologically confirmed stage I‑IIIB NSCLC between December 2013 and October 2014. A prime immunotherapy (9.1x107 cells/dose) and a single boost (8.2x107 cells/dose) were administered 1 month apart intradermally and the patients were evaluated for immunological and clinical response. DC immunotherapy was well tolerated, with no serious adverse events. There was a single incidence of grade 1 fever, chills and fatigue. Out of the 16 patients enrolled, 11 patients showed stable disease and 5 showed disease progression. There was a significant increase in IFN‑γ expression on day 60 vs. day 0 (P=0.048). An increasing trend in the mean cluster of differentiation (CD)4:CD8 values of day 30 and day 90 was observed, but this was not significant. The present study established that DCs primed with rMAGE‑3 and rSurvivin may be used in NSCLC treatment. However, a larger study is required to address prominent issues, including secretion of immunosuppressive cytokines and mechanisms of tumour escape from immune surveillance. Several factors associated with the manufacturing and quality of immunotherapy also require standardisation.

View Figures

View References

1	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc. 83:584–594. 2008. View Article : Google Scholar
2	Reck M: What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol. 23 suppl 8:viii28–viii34. 2012. View Article : Google Scholar : PubMed/NCBI
3	Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, Niederwieser D and Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 196:137–151. 1996. View Article : Google Scholar : PubMed/NCBI
4	Sallusto F and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 179:1109–1118. 1994. View Article : Google Scholar : PubMed/NCBI
5	He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L and Katsanis E: Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol Immunother. 50:31–40. 2001. View Article : Google Scholar : PubMed/NCBI
6	Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1:1297–1302. 1995. View Article : Google Scholar : PubMed/NCBI
7	Schuler G and Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med. 186:1183–1187. 1997. View Article : Google Scholar : PubMed/NCBI
8	Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature. 392:245–252. 1998. View Article : Google Scholar : PubMed/NCBI
9	Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM and Engleman EG: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA. 98:8809–8814. 2001. View Article : Google Scholar : PubMed/NCBI
10	Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK and Morse MA: Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer. 82:121–124. 1999. View Article : Google Scholar : PubMed/NCBI
11	Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, Barassi F, Santambrogio L, Coggi G and Bosari S: Survivin gene expression in early-stage non-small cell lung cancer. J Pathol. 200:620–626. 2003. View Article : Google Scholar : PubMed/NCBI
12	Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, Nguyen DM and Schrump DS: Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg. 71:295–302. 2001. View Article : Google Scholar : PubMed/NCBI
13	US Department of Health and Human Services, National Institutes of Health, National Cancer Institute: Common terminology criteria for adverse events. version, 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfOctober. 2014
14	Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J and Yannelli J: Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol. 22:2808–2815. 2004. View Article : Google Scholar : PubMed/NCBI
15	Kim D, Jeon C, Kim JH, Kim MS, Yoon CH, Choi IS, Kim SH and Bae YS: Cytoplasmic transduction peptide (CTP): New approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res. 312:1277–1288. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, et al: T-cell epitope mapping by flow cytometry. Nat Med. 4:975–978. 1998. View Article : Google Scholar : PubMed/NCBI
17	Bapsy PP, Sharan B, Kumar C, Das RP, Rangarajan B, Jain M, Attili Suresh VS, Subramanian S, Aggarwal S, Srivastava M and Vaid A: Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy. 16:234–244. 2014. View Article : Google Scholar : PubMed/NCBI
18	Sabado RL, Miller E, Spadaccia M, Vengco I, Hasan F and Bhardwaj N: Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. J Vis Exp. 2013. View Article : Google Scholar : PubMed/NCBI
19	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
20	Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
21	Dy GK and Adjei AA: Novel targets for lung cancer therapy: Part II. J Clin Oncol. 20:3016–3028. 2002. View Article : Google Scholar : PubMed/NCBI
22	Dy GK and Adjei AA: Novel targets for lung cancer therapy: Part I. J Clin Oncol. 20:2881–2894. 2002. View Article : Google Scholar : PubMed/NCBI
23	Liu X, Sun N, Dong Y, Li J, Liu Y, Ren Y, Yang C, Zhang L, Zhou Y, Tong Z, et al: Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells. Int Immunopharmacol. 25:416–424. 2015. View Article : Google Scholar : PubMed/NCBI
24	Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, et al: Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother. 62:1381–1392. 2013. View Article : Google Scholar : PubMed/NCBI
25	Cheever MA and Higano CS: PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 17:3520–3526. 2011. View Article : Google Scholar : PubMed/NCBI
26	Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K and Bonehill A: Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 56:1513–1537. 2007. View Article : Google Scholar : PubMed/NCBI